DOCSLIB.ORG

Combined Use of Trazodone-Naltrexone Versus Clonidine-Naltrexone in Rapid Withdrawal from Methadone Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Use of Trazodone-Naltrexone Versus Clonidine-Naltrexone in Rapid Withdrawal from Methadone Treatment Drug and Alcohol Dependence 59 (2000) 287–294 www.elsevier.com/locate/drugalcdep Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study Gino Pozzi *, Gianluigi Conte, Sergio De Risio Clinical Psychiatry and Substance Dependence Unit, Institute of Psychiatry and Psychology, Faculty of Medicine ‘Agostino Gemelli’, Catholic Uni6ersity of the Sacred Heart, 00168 Rome, Italy Received 11 June 1999; received in revised form 8 October 1999; accepted 12 October 1999 Abstract Trazodone is a non-tricyclic antidepressant drug with specific antagonistic activities at 5-HT2 and alpha-1 adrenoceptors. We test the efficacy of trazodone (T) compared with clonidine (C) in rapid opiate detoxification (ROD) from methadone after reduction to a daily maintenance dose 520 mg. Forty five inpatients were consecutively assigned either to T (n=30) or to C (n=15) treatment in a 7-day ROD protocol with naltrexone administration starting at day 4. The maximum daily dosage was 800 mg for T and 1.2 mg for C. The retention rate was similar in both groups (93.3%). Overall, T was as effective as C in the ROD protocol. T was slightly superior in controlling some subjective and psychological symptoms, but not under naltexone challenge. No severe adverse effects were observed. We conclude that T is effective, safe and well-tolerated in acute withdrawal from methadone. Further investigation is needed to test the effectiveness and safety of T in ultra-rapid protocols and its usefulness in long-term administration to detoxified addicts. © 2000 Elsevier Science Ireland Ltd. All rights reserved. Keywords: Opiate withdrawal; Naltrexone; Trazodone; Clonidine 1. Introduction Gossop and Strang, 1991; Kanof et al., 1993). Apart from subjective distress, such symptoms may provoke Long-term methadone maintenance is a treatment of resumption of street drug use in a high percentage of choice for large groups of opiate addicts aimed at clients. Shortening the so-called protracted or sec- stopping the use of illicit drugs, which dramatically ondary abstinence is made possible by adding opioid improves physical health and social adjustment (Coun- antagonists, with the advantage that clients directly cil on Addiction Psychiatry, 1994). Still, the discontinu- begin a maintenance program with naltrexone. Tech- ation of methadone medication may constitute a niques that precipitate opioid withdrawal by naloxone further stage of treatment to comply with other types of or naltrexone administration without anesthesia or drug-free therapeutic intervention and/or to complete heavy sedation are currently named rapid opioid detox- rehabilitation. Clinical studies demonstrate that metha- ification (ROD). On the whole, ROD techniques are done withdrawal may cause severe symptomatology, suitable for selected clients who have failed standard including classical opioid withdrawal symptoms and a detoxification treatment or desire an expedited detoxifi- true organic mood syndrome, starting when the daily cation for psychological or social reasons (O’Connor methadone dose is decreased below 20 mg and reaching and Kosten, 1988). a maximal levels a few weeks after the methadone dose The role of presynaptic 2-adrenoceptors in reducing tapering has been completed (Gossop et al., 1987; morphine withdrawal response at the locus coeruleus is a well-established (Aghajanian, 1978) and the 2-stimu- lant drug clonidine is commonly used as an effective * Corresponding author. Tel.: +39-6-30154573; fax: +39-6- 30154163. anti-withdrawal medication in the management of E-mail address: [email protected] (G. Pozzi) heroin addiction (Gold et al., 1978) and methadone 0376-8716/00/$ - see front matter © 2000 Elsevier Science Ireland Ltd. All rights reserved. PII: S0376-8716(99)00125-8 288 G. Pozzi et al. / Drug and Alcohol Dependence 59 (2000) 287–294 withdrawal (Charney et al., 1981). Subsequently, other withdrawal signs and may be further potentiated by a 2-agonists have been tested in preclinical studies of m-CPP exerting its agonistic activity on 5-HT1 recep- a morphine dependence, such as lofexidine (Shearman et tors and on 2-adrenoceptors. Anyhow, the metabolite al., 1980), guanfacine (Boccafusco et al., 1984), ti- seems to be only partially involved in the anti-with- zanidine (Pinelli et al., 1998). Lofexidine was also ad- drawal action of the parent compound and both ministered to humans for the management of molecules act at both spinal and supra-spinal levels non-precipitated opioid withdrawal in open and con- (Silvestrini and Valeri, 1986; Valeri et al., 1988, 1989, trolled studies (Schubert et al., 1984; Bearn et al., 1988; 1991b). Furthermore, 5-HT reuptake inhibition may Kahn et al., 1997), but clonidine remains the drug of play a role in the modulation of noradrenergic neurons reference in ROD treatments (Charney et al., 1986; hyperactivity at the locus coeruleus (Akaoka and As- Gold, 1993). ton-Jones, 1993). Trazodone is a triazolopyridine derivative that exerts complex effects on the CNS at different levels, partly by 1.1. Aim of the study means of its active metabolite methachlorophenylpiper- azine (m-CPP). As an antidepressant drug, trazodone is Starting from these preclinical evidences and previous devoid of the typical aminergic properties of tricyclics, open clinical studies in the management of non-precipi- showing specific adrenolytic and antiserotonergic ef- tated opiate withdrawal, we decided to test the clinical fects, moderate anti-histaminergic and very little or no efficacy of trazodone in comparison with clonidine anticholinergic and antidopaminergic activities. The under controlled conditions in a 7-day inpatient trial of a parent compound is a strong 1-antagonist with a more rapid detoxification from methadone treatment. a a than 10-fold greater affinity for 1 than for 2-adreno- ceptors; furthermore, it acts as a selective antagonist at 5-HT2 receptors and also as a 5-HT reuptake inhibitor, though over ten times less potent than fluoxetine. The 2. Materials and methods active metabolite m-CPP is a 5-HT1b agonist and a weak 5-HT2 antagonist, and seems unrelated to antide- 2.1. Sampling pressant and sedative–hypnotic effects (Taylor et al., 1980; Riblet and Taylor, 1981; Richelson and Nelson, Patients were enrolled from a waiting list of subjects 1984; Valeri et al., 1988; Richelson, 1990; Marek et al., requiring detoxification from methadone at the Drug 1992; Rotzinger et al., 1998). Trazodone and m-CPP Dependence Unit of the ‘Agostino Gemelli’ University share also antinociceptive properties, which are consid- Hospital in Rome during the period 1995–1997. The ered relevant to the antidepressant activity, exerted treatment costs were covered by the Italian National both through interactions with the opioid system and Health Service. Inpatient ROD was preceded by an through pathways not affected by naloxone (Valeri et outpatient phase of treatment aimed at tapering metha- al., 1991a). done maintenance dosage to 20 mg/day or less. Clinical The use of trazodone in the management of sub- evaluation during the preparation time was performed stance withdrawal syndromes was predicted by some of on a weekly basis, including urinanalysis for opiates its neuropharmacological activities (Riblet and Taylor, and other drugs of abuse. Low-dose psychoactive med- 1981), through different mechanisms from clonidine, ication (excluding clonidine or trazodone) was allowed a since trazodone does not downregulate presynaptic 2 in selected cases for mood and anxiety disorders, or for receptors by direct effect (Price et al., 1986). Open sleeplessness. clinical studies were performed since the late 1970s with Subjects fulfilling inclusion and exclusion criteria encouraging results in detoxification from opiates listed in Table 1 were asked for consent and were (Fedeli et al., 1979) and alcohol (Roccatagliata et al., informed that they could change their mind at any time 1980); trazodone was also proposed for the relief of about the ROD treatment. If so, as well as in case of cocaine withdrawal symptoms (Small and Purcell, failure of the treatment for any reason, they were 1985). More recently, trazodone did well in the man- re-stabilized on 20 mg/day of oral methadone and agement of benzodiazepine dependence in open and referred to outpatient facilities without prejudice for controlled trials (Ansseau and DeRoeck, 1993; Rickels further therapy. et al., 1999). Further preclinical in vivo investigation Patients enrolled in the study were consecutively has amplified our knowledge about the role of tra- assigned either to trazodone or to clonidine treatment zodone in opioid dependence and precipitated with- on a consecutive basis with a 2:1 ratio. All patients drawal at doses similar to those employed in the underwent physical and laboratory examination at the treatment of mood disorders in humans. In particular, beginning of hospitalization. None had abnormal blood a the selective adrenolytic effects of trazodone on 1 chemistry or ECG recording that could counterindicate receptors are responsible for the suppression of opiate the ROD treatment for clinical reasons. G. Pozzi et al. / Drug and Alcohol Dependence 59 (2000) 287–294 289 2.2. Ratings The checklist was completed by a trained medical doctor who was blind to study conditions. The evalua- Withdrawal responses were measured by means of a tion took about 30 min at each rating and was per- 27-item rating scale, specifically devised for the mea- formed daily in the late morning. surement
Load more

Recommended publications
  • Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A
    1 Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A. Ban By the mid-1990s the pioneering generation in neuropsychopharmacology was fading away. To preserve their legacy the late Oakley Ray (1931-2007), at the time Secretary of the American College of Neuropsychopharmacology (ACNP), generated funds from Solway Pharmaceuticals for the founding of the ACNP-Solway Archives in Neuropsychopharmacology. Ray also arranged for the videotaping of interviews (mainly by their peers) with the pioneers, mostly at annual meetings, to be stored in the archives. Herbert Kleber was interviewed by Andrea Tone, a medical historian at the Annual Meeting of the College held in San Juan, Puerto Rico, on December 7, 2003 (Ban 2011a; Kleber 2011a). The endeavor that was to become known as the “oral history project” is based on 235 videotaped interviews conducted by 66 interviewers with 213 interviewees which, on the basis of their content, were divided and edited into a 10-volume series produced by Thomas A. Ban, in collaboration with nine colleagues who were to become volume editors. One of them, Herbert Kleber, was responsible for the editing of Volume Six, dedicated to Addiction (Kleber 2011b). The series was published by the ACNP with the title “An Oral History of Neuropsychopharmacology Peer Interviews The First Fifty Years” and released at the 50th Anniversary Meeting of the College in 2011 (Ban 2011b). Herbert Daniel Kleber was born January 19, 1934, in Pittsburgh, Pennsylvania. His family’s father’s side was from Vilnius, Lithuania, and the Mother’s side was from Germany. Both families came to the United State during the first decade of the 20th century.
    [Show full text]
  • Advances in Opioid Antagonist Treatment for Opioid Addiction
    Advances in Opioid Antagonist Treatment for Opioid Addiction a, a b Walter Ling, MD *, Larissa Mooney, MD , Li-Tzy Wu, ScD KEYWORDS • Addiction treatment • Depot naltrexone • Opioid dependence • Relapse KEY POINTS • The major problem with oral naltrexone is noncompliance. Administration of naltrexone as an intramuscular injection may be less onerous and improve compliance because it occurs only once a month (ie, extended-release depot naltrexone). • To initiate treatment with extended-release depot naltrexone, steps should be taken to ensure that the patient is sufficiently free from physical dependence on opioids (eg, detoxification). • Research on naltrexone in combination with other medications suggests many opportu- nities for studying mixed receptor activities in the treatment of opioid and other drug addictions. PERSPECTIVE ON OPIOID ANTAGONIST TREATMENT FOR ADDICTION Naltrexone, an opioid antagonist derived from the analgesic oxymorphone, was synthesized as EN-1639A by Blumberg and colleagues in 1967. Four years later, in 1971, naltrexone was selected for high-priority development as a treatment for opioid addiction by the Special Action Office for Drug Abuse Prevention, an office created by President Nixon and put under the leadership of Dr Jerome Jaffe. Extinction Model The rationale for the antagonist approach to treating opioid addiction had been advanced by Dr Abraham Wikler a decade earlier, based largely on the extinction model explored in animal behavioral studies. It was believed that by blocking the euphorogenic effects of opioids at the opioid receptors, opiate use would become Disclosures: Dr Ling has served as a consultant to Reckitt Benckiser Pharmaceuticals and to Alkermes, Inc. Dr Mooney and Dr Wu report no relationships with commercial companies with any interest in the article’s subject matters.
    [Show full text]
  • Flashbacks and HPPD: a Clinical-Oriented Concise Review
    Isr J Psychiatry Relat Sci - Vol. 51 - No 4 (2014) Flashbacks and HPPD: A Clinical-oriented Concise Review Arturo G. Lerner, MD,1-2 Dmitri Rudinski, MD,1 Oren Bor, MD,1 and Craig Goodman, PhD1 1 Lev Hasharon Mental Health Medical Center, Pardessya, Israel 2 Sackler School Of Medicine, Tel Aviv University, Ramat Aviv, Israel INTRODUCTION ABSTRACT Hallucinogens encompass a group of naturally occurring A unique characteristic of LSD, LSD-like and substances and synthetic substances (1) which may trigger a transient with hallucinogenic properties is the recurrence of some and generally reversible state of intoxication characterized or all the hallucinogenic symptoms which had appeared by perceptual disturbances primarily visual in nature, often during the intoxication after the immediate effects of the referred to as “trips” (2, 3). A unique characteristic of LSD substance had worn off. This recurring syndrome, mainly (lysergic acid diethylamide) and LSD-like substances is the visual, is not clearly understood. The terms Flashback total or partial recurrence of perceptual disturbances which and Hallucinogen Persisting Perception Disorder (HPPD) appeared during previous intoxication and reappeared in have been used interchangeably in the professional the absence of voluntarily or involuntarily recent use (1-3). literature. We have observed at least two different This syndrome is still poorly understood (2, 3). LSD is the recurrent syndromes, the first Flashback Type we refer prototype of synthetic hallucinogenic substances and it is to as HPPD I, a generally short-term, non-distressing, probably the most investigated hallucinogen associated benign and reversible state accompanied by a pleasant with the etiology of this condition.
    [Show full text]
  • Novel Algorithms for the Prophylaxis and Management of Alcohol Withdrawal Syndromes–Beyond Benzodiazepines
    Novel Algorithms for the Prophylaxis and Management of Alcohol Withdrawal Syndromes–Beyond Benzodiazepines José R. Maldonado, MD KEYWORDS Alcohol withdrawal Withdrawal prophylaxis Benzodiazepines Anticonvulsant agents Alpha-2 agonists Delirium tremens KEY POINTS Ethanol affects multiple cellular targets and neural networks; and abrupt cessation results in generalized brain hyper excitability, due to unchecked excitation and impaired inhibition. In medically ill, hospitalized subjects, most AWS cases (80%) are relatively mild and un- complicated, requiring only symptomatic management. The incidence of complicated AWS among patients admitted to medical or critical care units, severe enough to require pharmacologic treatment, is between 5% and 20%. Despite their proven usefulness in the management of complicated AWS, the use of BZDP is fraught with potential complications. A systematic literature review revealed that there are pharmacologic alternatives, which are safe and effective in the management of all phases of complicated AWS. BACKGROUND Alcohol use disorders (AUDs) are maladaptive patterns of alcohol consumption mani- fested by symptoms leading to clinically significant impairment or distress.1 Ethanol is the second most commonly abused psychoactive substance (second to caffeine) and AUD is the most serious drug abuse problem in the United States2 and worldwide.3 The lifetime prevalences of Diagnostic and Statistical Manual of Mental Disorders,4thedi- tion, alcohol abuse and dependence were 17.8% and 12.5%, respectively; the total life- time prevalence for any AUD was 30.3%.4 Alcohol consumption-related problems are the Psychosomatic Medicine Service, Emergency Psychiatry Service, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Suite 2317, Stan- ford, CA 94305-5718, USA E-mail address: [email protected] Crit Care Clin 33 (2017) 559–599 http://dx.doi.org/10.1016/j.ccc.2017.03.012 criticalcare.theclinics.com 0749-0704/17/ª 2017 Elsevier Inc.
    [Show full text]
  • ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
    The ASAM NATIONAL The ASAM National Practice Guideline 2020 Focused Update Guideline 2020 Focused National Practice The ASAM PRACTICE GUIDELINE For the Treatment of Opioid Use Disorder 2020 Focused Update Adopted by the ASAM Board of Directors December 18, 2019. © Copyright 2020. American Society of Addiction Medicine, Inc. All rights reserved. Permission to make digital or hard copies of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for commercial, advertising or promotional purposes, and that copies bear this notice and the full citation on the fi rst page. Republication, systematic reproduction, posting in electronic form on servers, redistribution to lists, or other uses of this material, require prior specifi c written permission or license from the Society. American Society of Addiction Medicine 11400 Rockville Pike, Suite 200 Rockville, MD 20852 Phone: (301) 656-3920 Fax (301) 656-3815 E-mail: [email protected] www.asam.org CLINICAL PRACTICE GUIDELINE The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update 2020 Focused Update Guideline Committee members Kyle Kampman, MD, Chair (alpha order): Daniel Langleben, MD Chinazo Cunningham, MD, MS, FASAM Ben Nordstrom, MD, PhD Mark J. Edlund, MD, PhD David Oslin, MD Marc Fishman, MD, DFASAM George Woody, MD Adam J. Gordon, MD, MPH, FACP, DFASAM Tricia Wright, MD, MS Hendre´e E. Jones, PhD Stephen Wyatt, DO Kyle M. Kampman, MD, FASAM, Chair 2015 ASAM Quality Improvement Council (alpha order): Daniel Langleben, MD John Femino, MD, FASAM Marjorie Meyer, MD Margaret Jarvis, MD, FASAM, Chair Sandra Springer, MD, FASAM Margaret Kotz, DO, FASAM George Woody, MD Sandrine Pirard, MD, MPH, PhD Tricia E.
    [Show full text]
  • Myrtle Beach, SC May 24, 2019 New Drug Update 2019* *Presentation
    New Drug Update 2019* *Presentation by Daniel A. Hussar, Ph.D. Dean Emeritus and Remington Professor Emeritus Philadelphia College of Pharmacy University of the Sciences Objectives: After attending this program, the participant will be able to: 1. Identify the new therapeutic agents and explain their appropriate use. 2. Identify the indications and mechanisms of action of the new drugs. 3. Identify the most important adverse events and other risks of the new drugs. 4. State the route of administration for each new drug and the most important considerations regarding dosage and administration. 5. Compare the new therapeutic agents with older medications to which they are most similar in properties and/or use, and identify the most important advantages and disadvantages of the new drugs. New Drug Comparison Rating (NDCR) system 5 = important advance 4 = significant advantage(s) (e.g., with respect to use/effectiveness, safety, administration) 3 = no or minor advantage(s)/disadvantage(s) 2 = significant disadvantage(s) (e.g., with respect to use/effectiveness, safety, administration) 1 = important disadvantage(s) Additional information The Pharmacist Activist monthly newsletter: www.pharmacistactivist.com Myrtle Beach, SC May 24, 2019 Erenumab-aooe (Aimovig – Amgen; Novartis) Agent for Migraine 2018 New Drug Comparison Rating (NDCR) = Indication: Administered subcutaneously for the preventive treatment of migraine in adults Comparable drugs: Beta-adrenergic blocking agents (e.g., propranolol); (fremanezumab [Ajovy] and galcanezumab [Emgality]
    [Show full text]
  • Phannacotherapy in the Treabnent of Drug Dependence: Options to Strengthen Effectiveness Sarah Welch & John Strang
    Advances in Psychiatric Treatment (1999), vol. 5, pp. 427-434 Phannacotherapy in the treabnent of drug dependence: options to strengthen effectiveness Sarah Welch & John Strang Treatment ofpeople with drug problems requires a consideration of those inviduals in their personal Dependence andsocialcontext, whilebeingmindfulofthecomplex interactionofgeneticand developmental influences. Approaches to treatment should reflect this often Identifying the presence or absence of the depen­ complex aetiology and phenomenology, and the dence syndromeis importantin planning treatment. totality of treatment will typically include social, Dependence is a spectrum, and the therapist needs psychological, educational and pharmacological to developexperience in recognising degrees ofsever­ therapies. Treatment should result in a health benefit; ity. The dependencesyndromeis a clusterof physio­ consequently thegoals oftreatmentshouldbetailored logical, behavioural andcognitive phenomena (leD­ to the health care needs ofthe individual. Thus, with 10; World Health Organization, 1992; see Box 1). many patients, treatment will includeabstinence as Apart from the management ofoverdose, which an explicit objective, whereas with other patients, may, ofcourse, affect those who misusedrugs only intermediate goals, such as reduction of harmful once, the majority of pharmacotherapies are injecting, maybe more realistic and achievable. designed for use by those who have, or have had, Enthusiasm for new pharmacotherapies mustbe some or all of the features of the dependence
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]
  • HHS Guide for Clinicians on the Appropriate Dosage Reduction Or
    This HHS Guide for Clinicians on the Appropriate Dosage HHS Guide for Clinicians on the Reduction or Discontinuation of Long-Term Opioid Analgesics provides advice to clinicians who are contemplating or initiating a reduction in opioid dosage or discontinuation Appropriate Dosage Reduction of long-term opioid therapy for chronic pain. In each case the clinician should review the risks and benefits of the or Discontinuation of current therapy with the patient, and decide if tapering is appropriate based on individual circumstances. Long-Term Opioid Analgesics After increasing every year for more than a decade, annual needs.2,3,4 Coordination across the health care team is critical. opioid prescriptions in the United States peaked at 255 million in Clinicians have a responsibility to provide or arrange for 2012 and then decreased to 191 million in 2017.i More judicious coordinated management of patients’ pain and opioid-related opioid analgesic prescribing can benefit individual patients as problems, and they should never abandon patients.2 More well as public health when opioid analgesic use is limited to specific guidance follows, compiled from published guidelines situations where benefits of opioids are likely to outweigh risks. (the CDC Guideline for Prescribing Opioids for Chronic Pain2 At the same time opioid analgesic prescribing changes, such and the VA/DoD Clinical Practice Guideline for Opioid Therapy as dose escalation, dose reduction or discontinuation of long- for Chronic Pain3) and from practices endorsed in the peer- term opioid analgesics, have potential to harm or put patients at reviewed literature. risk if not made in a thoughtful, deliberative, collaborative, and measured manner.
    [Show full text]
  • Development of Cocaine Hydrolase for Therapeutic Treatment of Cocaine Abuse
    University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2016 DEVELOPMENT OF COCAINE HYDROLASE FOR THERAPEUTIC TREATMENT OF COCAINE ABUSE Xiabin Chen University of Kentucky, [email protected] Digital Object Identifier: http://dx.doi.org/10.13023/ETD.2016.289 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Chen, Xiabin, "DEVELOPMENT OF COCAINE HYDROLASE FOR THERAPEUTIC TREATMENT OF COCAINE ABUSE" (2016). Theses and Dissertations--Pharmacy. 59. https://uknowledge.uky.edu/pharmacy_etds/59 This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless an embargo applies.
    [Show full text]
  • Clonidine, Lofexidine and Similar Medications for the Management of Opioid Withdrawal
    Cochrane Database of Systematic Reviews Alpha2-adrenergic agonists for the management of opioid withdrawal (Review) Gowing L, Farrell M, Ali R, White JM Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD002024. DOI: 10.1002/14651858.CD002024.pub5. www.cochranelibrary.com Alpha2-adrenergic agonists for the management of opioid withdrawal (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Alpha2-adrenergic agonists for the management of opioid withdrawal Linda Gowing1, Michael Farrell2, Robert Ali1, Jason M White3 1Discipline of Pharmacology, University of Adelaide, Adelaide, Australia. 2National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. 3School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Contact address: Linda Gowing, Discipline of Pharmacology, University of Adelaide, Frome Road, Adelaide, South Australia, 5005, Australia. [email protected]. Editorial group: Cochrane Drugs and Alcohol Group. Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 5, 2016. Review content assessed as up-to-date: 7 January 2016. Citation: Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD002024. DOI: 10.1002/14651858.CD002024.pub5. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ABSTRACT Background Withdrawal is a necessary step prior to drug-free treatment or as the endpoint of long-term substitution treatment.
    [Show full text]
  • Hydroxychloroquine (All Populations Monograph)
    3/17/2020 Clinical Pharmacology powered by ClinicalKey Hydroxychloroquine (All Populations Monograph) Indications/Dosage expand all | collapse all Labeled malaria rheumatoid arthritis malaria prophylaxis systemic lupus erythematosus (SLE) Off-Label, Recommended coronavirus disease 2019 (COVID-19) † severe acute respiratory syndrome coronavirus lupus nephritis † 2 (SARS-CoV-2) infection † polymorphous light eruption † † Off-label indication Per the manufacturer, this drug has been shown to be active against most strains of the following microorganisms either in vitro and/or in clinical infections: Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax. NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data only have not been established in adequate and well-controlled clinical trials. This drug may also have activity against the following microorganisms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, exclusion from this list does not necessarily negate the drug’s activity against the organism. For the treatment of malaria due to susceptible strains of P. falciparum, P. knowlesi†, P. malariae, P. ovale, and P. vivax https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=300&type=0&printSections=monindi&printSections=monsup&printSections=mon… 1/87 3/17/2020 Clinical Pharmacology powered by ClinicalKey Oral dosage Adults 13 mg (10 mg base)/kg/dose [Max: 800 mg (620 mg base)/dose] PO, then 6.5 mg (5 mg base)/kg/dose [Max: 400 mg (310 mg base)/dose] PO at 6, 24, and 48 hours after the initial dose.[41806] [64059] For P.
    [Show full text]